Barbara Eichhorst, MD of the University of Cologne, Cologne, Germany, discusses the treatments of elderly chronic lymphocytic leukemia (CLL) patients and the use of novel therapies. There are novel therapies that are significantly better tolerated by the elderly. However, if combination therapies are used in the future, this could be difficult for this population, particularly from a mental point of view. Dr Eichhorst mentions how available combination treatments, which are better tolerated in the general sense, may not be applicable to the elderly patient population. For example with venetoclax, there is a ramp-up period and therefore it may not suitable for an elderly person. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.